Shilpa Medicare To Begin FY27 ADC Biosimilar Human Trials As Tax Rates Normalize Around 25%

Market snapshot: Shilpa Medicare delivered a robust Q1 FY27 performance, marked by its highest-ever quarterly revenue and a strong profit surge. The company is advancing its high-value pipeline, with its first Antibody-Drug Conjugate biosimilar set for human trials in FY27. Despite a temporary regulatory setback for its CDMO partner Unicycive Therapeutics, Shilpa Medicare's operational growth remains solid across API and formulations.

Data Snapshot

• Consolidated Net Profit jumped 115.14% YoY to ₹100.88 crore in Q1 FY27 from ₹46.89 crore in Q1 FY26.
• Consolidated Revenue from Operations grew 44.9% YoY to ₹465.78 crore in Q1 FY27 from ₹321.46 crore in Q1 FY26.
• Shilpa Medicare recorded a one-time deferred tax liability reversal of ₹26.84 crore in Q1 FY27, making the effective tax rate negative at -2.88%.
• Formulations segment revenue grew 102.04% YoY to ₹198 crore, while the API segment grew 15% YoY to ₹260 crore in Q1 FY27.
• Shilpa Biocare acquired a 30.4% equity stake in Spain-based Gate2Brain S.L. for a total of €7 million, combining €0.5 million cash and €5.5 million in equity-for-services.

What's Changed

• Shilpa Medicare's consolidated revenue from operations reached a multi-quarter high of ₹465.78 crore in Q1 FY27 from ₹321.46 crore in Q1 FY26.
• Effective tax rate turned negative (-2.88%) in Q1 FY27 compared to 5.43% in Q1 FY26 due to a ₹26.84 crore deferred tax reversal.
• Formulations vertical has overtaken API as the primary growth accelerator, growing 102.04% YoY to ₹198 crore.

Key Takeaways

• Strong Q1 FY27 Earnings: Consolidated net profit surged 115.14% YoY to ₹100.88 crore, backed by steady demand and tax reversals.
• ADC Program Progress: The company's first proprietary ADC biosimilar is on track to enter human clinical trials in FY27.
• Tax Reversal Rebound: Profitability was significantly boosted by a ₹26.84 crore deferred tax liability reversal, though future tax rates will normalize around 25%.
• CDMO Regulatory Impact: Partner Unicycive Therapeutics received a second FDA CRL for OLC on June 30, 2026, due to third-party manufacturing deficiencies, with plans to refile in Q3 (as stated in the source alert; not independently verified).

SAHI Perspective

Shilpa Medicare is successfully pivoting from a pure API-driven model to a high-margin formulation and biologics powerhouse. The exceptional doubling of formulations revenue to ₹198 crore shows strong execution. While the ₹100.88 crore net profit was heavily aided by a one-time ₹26.84 crore tax reversal, the underlying operational EBITDA margin of 30% demonstrates robust fundamental strength. The strategic €7 million investment in Barcelona-based Gate2Brain and the upcoming clinical trials for its first ADC biosimilar represent significant steps in its biological and central nervous system specialty portfolio.

Market Implications

The strong Q1 earnings and operational growth in formulations are highly positive for the stock, as evidenced by the 11.25% surge to close at ₹721.35 on August 5, 2026. However, the regulatory delay for Unicycive's Oxylanthanum Carbonate (OLC) remains a key watchpoint. Although the deficiencies lie with an unaffiliated third-party manufacturer and not Shilpa Medicare (which provides API and finished formulations), the commercialization delay push to FY27 affects the near-term milestone payments for Shilpa.

Trading Signals

Market Bias: Bullish

Strong formulation growth (+102% YoY) and steady EBITDA margins of 30% support a bullish outlook. Near-term earnings are well-supported, though investors should account for normalized tax rates of 25% in the coming quarters.

Overweight: Pharmaceuticals, Contract Development and Manufacturing (CDMO)

Trigger Factors:

• Human clinical trial initiation of the first ADC biosimilar in FY27.
• Resolution and refiling of Unicycive's NDA with the US FDA.
• Progress in the €7 million Gate2Brain investment and clinical batches production.

Time Horizon: Medium-term (3-12 months)

Industry Context

The Indian pharmaceutical sector is witnessing a shift towards specialized drug delivery systems, complex generics, and biologics. High-potency APIs and Antibody-Drug Conjugates (ADCs) are emerging as critical high-margin areas. Shilpa Medicare's commissioning of its integrated ADC facility in Dharwad positions it as one of the few Indian CDMOs offering end-to-end biological and cytotoxic payload capabilities, helping global innovators simplify supply chains.

Key Risks to Watch

• Tax Rate Normalization: Earnings in upcoming quarters will face higher tax expenses as the tax rate normalizes to around 25%.
• Regulatory Setbacks: Ongoing delays in FDA approvals for CDMO partners, such as Unicycive's second CRL for OLC, can defer expected supply revenues and milestones.
• Clinical Trial Risks: The first ADC biosimilar entering human trials in FY27 is subject to standard clinical development and regulatory approvals.

Recent Developments

Shilpa Medicare's wholly-owned arm, Shilpa Biocare, entered into a strategic equity partnership with Gate2Brain S.L. in June 2026, investing €7 million to acquire a 30.4% stake. Separately, in July 2026, Unicycive received a second FDA CRL for OLC due to third-party deficiencies, though efficacy and safety were not questioned. On August 5, 2026, Shilpa Medicare reported its highest-ever quarterly revenue of ₹465.78 crore for Q1 FY27.

Closing Insight

Shilpa Medicare is transitioning into a sophisticated CDMO and biopharma developer. While the Q1 tax benefit inflated net profits, the underlying 102% formulation growth and robust 30% EBITDA margins demonstrate structural progress that outweighs regulatory noise from its partner's manufacturing vendor.

High Performance Trading with SAHI.